All In Biotech

Drug Trial Radar · NCT03233854

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies

Phase 1 Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies

Last checked: Nov 19, 2026Latest source record: Nov 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

56

Actual

Start

Sep 1, 2017

Primary completion

Jun 20, 2023

Study completion Sep 1, 2035

Sponsor

Lead sponsor
Stanford UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
California Institute for Regenerative Medicine (CIRM)
First posted
Jul 31, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I trial studies the side effects of CD19/CD22 chimeric antigen receptor (CAR) T cells when given together with chemotherapy and NKTR-255, and to see how well they work in treating patients with CD19 positive B acute lymphoblastic leukemia that has come back or does not respond to treatment. A CAR is a genetically-engineered receptor made so that immune cells (T cells) can attack cancer cells by recognizing and responding to the CD19/CD22 proteins. These proteins are commonly found on diffuse large B-cell lymphoma and B acute lymphoblastic leukemia. Drugs used in chemotherapy, such as cyclophosphamide and fludarabine phosphate, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. NKTR-255 is an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. Giving CD19/CD22-CAR T cells and chemotherapy in combination with NKTR-255 may work better in treating patients with diffuse large B-cell lymphoma or B acute lymphoblastic leukemia.

Conditions

  • B Acute Lymphoblastic Leukemia
  • CD19 Positive
  • Minimal Residual Disease
  • Philadelphia Chromosome Positive

Interventions

  • Chimeric Antigen Receptor T-Cell TherapyBiological

    Given CD19/CD22 CAR T cells IV

  • CyclophosphamideDrug

    Given IV

  • Fludarabine PhosphateDrug

    Given IV

  • Laboratory Biomarker AnalysisOther

    Correlative studies

  • Questionnaire AdministrationOther

    Ancillary studies

  • NKTR-255Drug

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of dose limiting toxicities (DLTs) following chemotherapy preparative regimen and infusion of CD19/CD22 chimeric antigen receptor (CAR) T cellsTime frame: Up to 28 days
  2. Maximum tolerated dose of CD19/CD22 chimeric antigen receptor (CAR) T cells defined as the dose level immediately below the level at which the enrollment is stopped due to a dose limiting toxicityTime frame: Up to 28 days
  3. Rate of successful manufacture and expansion of the CD19/CD22 chimeric antigen receptor (CAR) T cells to satisfy the targeted dose level and meet the required release specifications outlined in the Certificate of AnalysisTime frame: Up to 15 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Stanford University, School of Medicine

    Palo Alto, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.